Intranasal sufentanil for cancer-associated breakthrough pain

Palliative Medicine

Volumn 23, Issue 1, 2009, Pages 54-58

  Good, Phillip ^a,e   Jackson, K ^b   Brumley, D ^c   Ashby, M ^d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BALLARAT HEALTH SERVICES   (Australia)

^d ROYAL HOBART HOSPITAL   (Australia)

^e CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

Author keywords

Breakthrough pain; Cancer; Opioid; Sufentanil

Indexed keywords

OPIATE; SUFENTANIL;

ARTICLE; BREATHING RATE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; NAUSEA; OPEN STUDY; OXYGEN SATURATION; PAIN ASSESSMENT; PATIENT COMPLIANCE; REPEATED DRUG DOSE; SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; AUSTRALIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSPECTIVE STUDIES; SUFENTANIL; TREATMENT OUTCOME;

EID: 58549109020     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269216308100249     Document Type: Article

References (12)

1. Portenoy RK, Hagen NA. Breakthrough pain: Definition, prevalence and characteristics. Pain 1990; 41: 273-281.
2. Therapeutic Guidelines Limited. Palliative Care Expert Group. Therapeutic guidelines: Palliative care. 2nd ed. North Melbourne, Vic.: Therapeutic Guidelines Ltd; 2005.
3. Stanley TH. The history and development of the fentanyl series. J Pain Symptom Manage 1992; 7(Suppl. 3): S3-S7.
4. Helmers JH, Noorduin H, Van Peer A, Van Leeuwen L, Zuurmond WW. Comparison of intravenous and intranasal sufentanil absorption and sedation. Can J Anaesth 1989; 36: 494-497.
5. Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: A pilot study. J Pain Symptom Manage 2000; 20: 253-258.
6. Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med 2000; 14: 57-58.
7. Harlos M. Palliative care incident pain and incident dyspnea protocol. Available from: Http://palliative.info/IncidentPain.htm; 2002 [accessed 18.02.2008]
8. Jackson K, Ashby M, Keech J. Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain. J Pain Symptom Manage 2002; 23: 450-452.
9. O'Neil, G, Paech, M, Wood, F. Preliminary clinical use of a patient-controlled intranasal analgesia (PCINA) device. Anaesth Intensive Care 1997; 25: 408-412.
10. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000; 88: 287-294.
11. Streisand JB, Varvel JR, Stanski DR, Le Maire L, Ashburn MA, Hague BI. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75: 223-229.
12. Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain 1999; 79: 303-312.